GALNT6 and cancer: Based on various statistical analyses of a large patient cohort, loss of GALNT6 protein expression could potentially serve as a prognostic marker to risk-stratify cancers of early clinical stage (stages I and II) and aid in selecting patients for more intensive adjuvant therapy or closer surveillance.